Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 31, 2014Phase III data for lenvatinib to be presented at ASCO
Eisai Inc. announced today results from the Phase III SELECT trial of investigational agent lenvatinib evaluating progression-free survival (PFS) in patients with progressive...
- May 28, 2014-- Pediatric Patients Aged 1 Month to Less Than 17 Years Now Have A New Option to Help Prevent Acute Chemotherapy-Induced Nausea and Vomiting --
Eisai Inc. and Helsinn Group today announced the Food and Drug Administration (FDA) approval of ALOXI® (palonosetron HCl) injection for the prevention of acute nausea and vomiting associated with...
- May 22, 2014- Companies Advance Multiple Co-discovery Programs for First-in-class Targets in Oncology -
H3 Biomedicine Inc., a biopharmaceutical company specializing in the discovery and development of precision oncology treatments, and Selvita (PL: SLV), one of the largest drug discovery companies...
-
May 14, 2014Data underscore breadth of oncology portfolio
Eisai Inc. announced today that 10 abstracts highlighting new study results will be presented during the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in...
- Apr 3, 2014- Company to Present Data on SF3B1 Program at a Symposium During the American Association for Cancer Research Annual Meeting 2014 -
H3 Biomedicine Inc., a biopharmaceutical company specializing in the discovery and development of precision medicines for oncology, announced today...
